xB3 004
Alternative Names: xB3™-IL-1RA; MTfp-antibody fusion - biOasis Technologies/AstraZeneca; xB 3 –IL1RA Fusion; xB3-hIgG1-IL1RA; xB3-004Latest Information Update: 06 May 2024
At a glance
- Originator MedImmune
- Developer AstraZeneca; biOasis Technologies
- Class Analgesics; Anti-inflammatories; Immunoglobulin fragments; Recombinant fusion proteins
- Mechanism of Action Interleukin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Encephalomyelitis; Fabry's disease; Multiple sclerosis; Neurodegenerative disorders; Neuropathic pain; Pain
Most Recent Events
- 20 Jun 2023 Discontinued - Preclinical for Encephalomyelitis in Canada (Parenteral) before June 2023
- 20 Jun 2023 Discontinued - Preclinical for Multiple sclerosis in Canada (Parenteral) before June 2023
- 20 Jun 2023 Discontinued - Preclinical for Neurodegenerative disorders in Canada (Parenteral) before June 2023